A study by Teh et al. revealed that the concurrent targeting of BCL2 and MCL1 was associated with long-term survival in AML mouse xenografts, in contrast to targeting a subset of proteins alone [118]. The gene discussed is BCL2; the disease is acute myeloid leukemia.